How should MSD balance efficacy and side effects in developing new vaccines for infectious diseases?

Introduction

Balancing efficacy and side effects in vaccine development is a critical challenge for MSD. This trade-off involves weighing the potential benefits of a highly effective vaccine against the risks of adverse reactions. I'll analyze this complex issue through the lens of product strategy, considering stakeholder impacts, metrics, and decision frameworks.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm assuming this is for a new vaccine in development. Could you confirm if we're looking at a specific disease or a broader vaccine platform?

Why it matters: Helps focus the analysis on relevant factors Expected answer: Specific disease (e.g., COVID-19 variant) Impact: Would tailor the approach to that disease's characteristics and urgency

• Business Context: Based on MSD's portfolio, I'm thinking this vaccine might be a potential blockbuster. How does this project align with our current revenue projections and strategic priorities?

Why it matters: Helps prioritize resources and risk tolerance Expected answer: High priority, significant revenue potential Impact: Would justify more aggressive development timeline and higher risk tolerance

• User Impact: Considering the global nature of infectious diseases, I'm assuming we're targeting a diverse population. Can you provide insights into the primary target demographics and any specific vulnerable groups?

Why it matters: Influences efficacy and side effect considerations for different populations Expected answer: Broad adult population, with focus on elderly and immunocompromised Impact: Would necessitate careful segmentation in clinical trials and analysis

• Technical: Given the complexity of vaccine development, I'm curious about our current technological capabilities. Are we leveraging any new platforms or adjuvants that might impact the efficacy-side effect balance?

Why it matters: Affects the potential range of efficacy and side effects we can achieve Expected answer: Using established platform with some novel elements Impact: Would inform the trade-off analysis based on known and unknown factors

• Timeline: Considering the urgency of infectious disease control, what's our target timeline for bringing this vaccine to market?

Why it matters: Influences the balance between speed and thoroughness in development Expected answer: Accelerated timeline due to public health need Impact: Would require careful consideration of fast-tracking certain processes while maintaining safety standards